Veeva Systems Inc.
Health Care · Health Care Technology
Structural: vertical cloud monopoly in life-sciences software - top 20 pharma all run Veeva for at least one mission-critical workflow; switching costs near-absolute once Vault holds clinical trial, regulatory submission and quality records of a multi-billion-dollar drug program.
Crossix (acquired 2019) added the patient-data leg, making Veeva the connective tissue between R&D, manufacturing and commercial in pharma.
(1) Vault CRM migration off $CRM Salesforce by 2030 expands TAM and recaptures the reseller margin; (2) AI agents layered on top of Vault data (clinical, quality, regulatory) are a natural monetization wedge with no comparable peer dataset; (3) ex-pharma verticalization (consumer products, chemicals via Vault Quality) extends the runway beyond the core life-sci customer; (4) FCF margin sustained above 40%, rule-of-50 profile; (5) net retention historically 110%+ on Vault.
(1) Salesforce divorce is a multi-year execution risk - pharma CRM migrations are slow and a botched cutover hands $CRM a re-entry; (2) GLP-1 era and biotech funding winter compress commercial-cloud seat growth at small/mid-biotech; (3) AI-native challengers (and pharma in-housing on $PLTR Foundry) could nibble at point workflows; (4) high-teens multiple of revenue prices in flawless Vault CRM landings; (5) FX and Europe pharma headwinds drag reported growth.
No major news in the last 7 days for VEEV - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.